| Name | Title | Contact Details |
|---|---|---|
Anju Chatterji |
Chief Technical Officer | Profile |
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.
OncoSec Medical Inc. is a biopharmaceutical company developing its ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical’s core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-modulating agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s clinical programs currently include three Phase 2 trials targeting metastatic melanoma Merkel cell carcinoma and cutaneous T-cell lymphoma conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in these indications it is also investigating additional indications and combination therapeutic approaches.
Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.
UNIConnect LC is a Sandy, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2014, Boston based Orig3n exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we`re on a mission to accelerate the future of regenerative medicine.